Peter S. Heeger
- PROFESSOR Medicine, Nephrology
M.D., University of Pennsylvania
- Peter S. Heeger, MD, is Professor of Medicine, Director of Transplant Research and a member of the Immunology Institute and the Recanati Miller Transplant Institute at the Icahn School of Medicine at Mount Sinai in New York. He leads the Clinical Trials in Organ Transplantation consortium, conducting trials to assess the utility of noninvasive biomarkers to predict outcomes in transplant recipients. His basic research interests are mechanisms of allograft injury and tolerance, with a focus on complement and T lymphocytes. He serves as current chair of the TTT NIH study section, is an active member of the American Society of Transplantation, and has authored >130 publications in the field.
ResearchSpecific Clinical/Research Interest: Transplant immunology, complement, T cells
Postdoctoral Fellows: Paolo Cravedi, Pragya Yadav, Divya Verghese, Carolina Purroy
Junior Faculty: Jessica Reid-Adam
Student Researchers: Francis Sheen, Ed Kwon, Douglas Mathern
Lab Manager: Denise Peace
Reasearch Assistants: Tina Yao, Riddhika Pandya, Linda Zhang, Abhishek Parmar
I lead a basic science lab in transplant immunology and complement/T cell interactions. I am also the Director of Transplant Research at Mount Sinai and oversee all clinical and translational transplant trials at the institution. Our group leads a multicenter international NIH trial on biomarkers as predictors of transplant outcome
Summary of Research Studies:
The research performed in my laboratory focuses on understanding the cellular and molecular immunologic events involved in rejection and tolerance of allogeneic organ grafts in mouse models and in humans. Using mouse models we assess a) how and where alloreactive T cell recognize antigens found in transplanted donor tissues and b) which induced effector mechanisms are essential for inducing graft pathology. Recently published work from our group has also delineated a new link between innate and adaptive immunity by demonstrating that alternative pathway complement components influence the strength of all T cell immune responses, including those directed at allogeneic tissues. Lessons derived from the animal studies are being ''translated'' into humans. I direct an NIH U01 multicenter trial to assess the utility of noninvasive markers to predict outcome in organ transplant recipients. The study is designed to provide a rational scientific foundation for therapeutic decision-making aimed at maximizing graft survival and minimizing toxicity in organ graft recipients.
Sawinski D, Uribarri J, Peace D, Yao T, Wauhop P, Trzcinka P, Ostrow K, Poggio ED, Heeger PS. 25-OH-vitamin D deficiency and cellular alloimmunity as measured by panel of reactive T cell testing in dialysis patients. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2010 Oct; 10(10).
Kalache S, Dinavahi R, Pinney S, Mehrotra A, Cunningham MW, Heeger PS. Anticardiac myosin immunity and chronic allograft vasculopathy in heart transplant recipients. Journal of immunology (Baltimore, Md. : 1950) 2011 Jul; 187(2).
Kwan WH, Hashimoto D, Paz-Artal E, Ostrow K, Greter M, Raedler H, Medof ME, Merad M, Heeger PS. Antigen-presenting cell-derived complement modulates graft-versus-host disease. The Journal of clinical investigation 2012 Jun; 122(6).
Kwan WH, van der Touw W, Paz-Artal E, Li MO, Heeger PS. Signaling through C5a receptor and C3a receptor diminishes function of murine natural regulatory T cells. The Journal of experimental medicine 2013 Feb; 210(2).
Reid-Adam J, Yang N, Song Y, Cravedi P, Li XM, Heeger P. Immunosuppressive effects of the traditional Chinese herb Qu Mai on human alloreactive T cells. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2013 May; 13(5).
Keslar KS, Lin M, Zmijewska AA, Sigdel TK, Tran TQ, Ma L, Bhasin M, Rao P, Ding R, Iklé DN, Mannon RB, Sarwal MM, Strom TB, Reed EF, Heeger PS, Suthanthiran M, Fairchild RL. Multicenter evaluation of a standardized protocol for noninvasive gene expression profiling. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2013 Jul; 13(7).
van der Touw W, Cravedi P, Kwan WH, Paz-Artal E, Merad M, Heeger PS. Cutting edge: Receptors for C3a and C5a modulate stability of alloantigen-reactive induced regulatory T cells. Journal of immunology (Baltimore, Md. : 1950) 2013 Jun; 190(12).
Ashoor I, Najafian N, Korin Y, Reed EF, Mohanakumar T, Ikle D, Heeger PS, Lin M. Standardization and cross validation of alloreactive IFNγ ELISPOT assays within the clinical trials in organ transplantation consortium. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2013 Jul; 13(7).
Hricik DE, Nickerson P, Formica RN, Poggio ED, Rush D, Newell KA, Goebel J, Gibson IW, Fairchild RL, Riggs M, Spain K, Ikle D, Bridges ND, Heeger PS. Multicenter Validation of Urinary CXCL9 as a Risk-Stratifying Biomarker for Kidney Transplant Injury. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2013 Oct; 13(10).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Heeger during 2012 and/or 2013. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- Oxford Immunotec, Inc.
Other Activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership.
- Alexion Pharmaceuticals, Inc.; Oxford Immunotec, Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Annenberg Building Floor 23rd Floor Room Room 23-04B
1468 Madison Avenue
New York, NY 10029